ID   22Rv1 R
AC   CVCL_4Y35
DR   cancercelllines; CVCL_4Y35
DR   Wikidata; Q54583382
RX   PubMed=21982118;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1045 ! 22Rv1
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 11
//
RX   PubMed=21982118; DOI=10.1186/1476-4598-10-126;
RA   O'Neill A.J., Prencipe M., Dowling C., Fan Y., Mulrane L.,
RA   Gallagher W.M., O'Connor D., O'Connor R., Devery A.M., Corcoran C.,
RA   Rani S., O'Driscoll L., Fitzpatrick J.M., Watson R.W.G.;
RT   "Characterisation and manipulation of docetaxel resistant prostate
RT   cancer cell lines.";
RL   Mol. Cancer 10:126.1-126.13(2011).
//